RESEARKA

The cited A/B receipts support a specific working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.

Citation Support

• source_1 Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
• source_2 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
• source_3 Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials
• source_4 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
• source_5 Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial